Latest irbesartan Stories
LONDON, April 16, 2015 /PRNewswire/ -- SummaryGBI Research, the leading business intelligence provider, has released its latest research, ''Antihypertensive Therapeutics in
New research report “Anti-Hypertensive Therapeutics in Major Developed Markets to 2020 – Increased Uptake of Combination Therapies to Offset Effects of Key Patent Expiries” elaborated by
Bristol-Myers Squibb Co said Thursday that it is recalling 64 million tablets of the blood pressure medicine Avalide in the US and Puerto Rico due to the potential for reduced effectiveness.
Most research in atrial fibrillation (AF) has focused on reducing stroke and other embolic events. Yet heart failure occurs more frequently in AF patients, but has not been the focus of intervention research.
A medication used for high blood pressure does not improve a common form of heart failure, according to new results from a large, international study.
Mylan has announced that its subsidiary, Mylan Pharmaceuticals, has received tentative approval from the FDA for its abbreviated new drug application for Irbesartan and hydrochlorothiazide tablets, 150mg/12.5mg and 300mg/12.5mg.
PITTSBURGH, June 16 /PRNewswire-FirstCall/ -- Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., has received tentative approval from the U.S.
- A hairdresser.